Video Experimental Relacionado
Updated: Jul 27, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Los stents que emiten fármacos en la intervención vascular
Rossella Fattori1, Tommaso Piva
1Department of Radiology, Cardiovascular Unit, University Hospital S Orsola, 40138, Bologna, Italy. ross@med.unibo.it
Lancet (London, England)
|January 28, 2003
Resumen
Los stents que liberan fármacos, como los recubiertos con sirolimus, previenen eficazmente la restenosis después de procedimientos coronarios. Este enfoque de administración local de fármacos ofrece una solución prometedora para la restenosis del stent, mejorando los resultados de los pacientes.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Cardiología Intervencionista Cardiología intervencionista.
- Ingeniería Biomédica Ingeniería Biomédica.
Sus antecedentes:
- La restenosis, o restenosis en el stent, es una complicación significativa después de la implantación de un stent coronario, impulsada por la hiperplasia neointimal.
- Los tratamientos actuales para la restenosis tienen un éxito limitado, lo que plantea desafíos clínicos y económicos.
- La administración local de fármacos a través de stents recubiertos ofrece un enfoque específico para inhibir la proliferación neointimal.
Objetivo del estudio:
- Evaluar la eficacia de los stents recubiertos de sirolimus en la prevención de la restenosis después de intervenciones coronarias percutáneas.
- Evaluar la seguridad y eficacia a largo plazo de la administración local de sirolimus.
Principales métodos:
- Se utilizaron ensayos multicéntricos que involucraron a pacientes sometidos a intervenciones coronarias percutáneas con stents recubiertos de sirolimus o con stents convencionales.
- Se siguió a los pacientes durante un máximo de 6 meses y 2 años para evaluar las tasas de restenosis y eventos adversos.
Principales resultados:
- Los stents recubiertos con sirolimus demostraron una reducción significativa de la restenosis, con 0% de restenosis observada a los 6 meses en comparación con el 27% en el grupo de control (p <0,001).
- El seguimiento de dos años confirmó la inhibición persistente de la restenosis y no hubo eventos adversos inesperados.
Conclusiones:
- La administración local de fármacos utilizando stents recubiertos de sirolimus es una estrategia altamente efectiva para prevenir la restenosis en el stent.
- Este enfoque tiene una promesa significativa para mejorar el manejo de la enfermedad de las arterias coronarias y reducir los costos de atención médica.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...